An interventional study of Informational Intervention and Survey Administration in Breast Carcinoma, sponsored by University of Michigan Rogel Cancer Center. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center — 5 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · University of Michigan Rogel Cancer Center.
Among the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center, this one is the 30th largest by planned enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2024, is one of 18 with no phase, and was the 45th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →5 of the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center are open now, in 1 country. Recruiting first, the newest first:
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Women only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Women only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Women only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 60–85 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 4 1
First in 1999; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 34 across the 36 interventional studies, 68 across the 11 observational. Of the 40 that completed or were terminated, 14 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Michigan Rogel Cancer Center is the lead sponsor of 325 studies on the registry; 49 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 31 (67%) have results posted.
5 of the studies in Breast Neoplasms by University of Michigan Rogel Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183126University of Michigan Rogel Cancer CenterPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | 2026-11 |
| NCT06100263University of Michigan Rogel Cancer CenterBreast Cancer Resiliency Through Exercise Program (B-REP) | 2026-12 |
| NCT05996107University of Michigan Rogel Cancer CenterStudy of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer | 2027-02 |
| NCT06915168University of Michigan Rogel Cancer CenterCIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer | 2027-03 |
| NCT07291414University of Michigan Rogel Cancer CenterA Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients | 2027-03-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial studies how well a chemotherapy-induced peripheral neuropathy (CIPN) decision aid works in improving chemotherapy decision making among patients with breast cancer. CIPN involves numbness or tingling in the hands or feet and is a debilitating side effect of several commonly used classes of cancer drugs. CIPN symptoms are typically minor at first but can progress with continued treatment to severe symptoms that can affect long-term function, falls risk, and quality of life. Symptoms sometimes resolve after treatment but in patients who experienced CIPN, symptoms are still present 1 year post-treatment in about two-thirds of patients and 3 years post-treatment in approximately half of the patients. Previous studies indicate patients lack awareness of long-term CIPN symptoms. A decision aid that provides information about permanent CIPN, that helps patients understand their treatment priorities, and prepares them for a discussion with their medical oncologist may lead to improvements in treatment decision making, satisfaction with decision making, and ultimately increase patient's achievement of their treatment goals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients receive the CIPN DecisionAid on study.
Other: Informational Intervention · Other: Survey Administration
Given CIPN DecisionAid
Ancillary studies
Change in decision preparedness
Will be assessed using Question #2 on the Awareness, Preparedness, and Confidence Survey.
Time frame: up to 12 weeks
Change in decision preparedness
Will be assessed using Question #2 on the Awareness, Preparedness, and Confidence Survey. A secondary analysis will be conducted using linear regression adjusting for the treatment (adjuvant versus \[vs\]. metastatic, paclitaxel vs. docetaxel, weekly vs. 3-weekly) and other baseline variables (e.g., age, chemotherapy-induced peripheral neuropathy \[CIPN\] severity).
Time frame: up to 12 weeks
Change in awareness
Will be assessed using Question #1 on the Awareness, Preparedness, and Confidence Survey.
Time frame: up to 12 weeks
Change in discussion confidence
Will be assessed using Question #3 on the Awareness, Preparedness, and Confidence Survey.
Time frame: up to 12 weeks
Change in decision preparedness
Will be assessed using Question #4 on the Awareness, Preparedness, and Confidence Survey.
Time frame: up to 12 weeks
Change in decision empowerment
Will be assessed using Question #5 on the Awareness, Preparedness, and Confidence Survey.
Time frame: up to 12 weeks
Discussion satisfaction
Will be assessed using Question #6 on the Satisfaction and Helpfulness Survey.
Time frame: up to 12 weeks
Decision satisfaction
Will be assessed using Question #7 on the Satisfaction and Helpfulness Survey.
Time frame: up to 12 weeks
Helpfulness
Will be assessed using Question #8 on the Satisfaction and Helpfulness Survey.
Time frame: up to 12 weeks
Taxane chemotherapy treatment decision
Will be assessed using Question #9 on the Satisfaction and Helpfulness Survey.
Time frame: up to 12 weeks
Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 28 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jul 2026 → Mar 2027 and completion Jul 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Michigan Rogel Cancer Center →